Red blood cell support and alloimmunization rate against erythrocyte antigens in patients undergoing hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 32, Issue 2, 2003, Pages 231-236

  Perseghin, P ^a   Balduzzi, A ^a   Galimberti, S ^b   Dassi, M ^a   Baldini, V ^a   Valsecchi, M G ^b   Pioltelli, P ^a   Bonanomi, S ^a   Faccini, P ^a   Rovelli, A ^a   Pogliani, E M ^a   Uderzo, C ^a  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Alloimmunization; RBC transfusion; Stem cell transplantation

Indexed keywords

ALLOANTIBODY; CYCLOSPORIN A; ERYTHROCYTE ANTIGEN; METHOTREXATE; RHESUS ANTIBODY; RHESUS E ANTIBODY; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGED; ALLOIMMUNIZATION; ANTIBODY DETECTION; ANTIBODY SCREENING; ARTICLE; AUTOTRANSPLANTATION; CHILD; CONTROLLED STUDY; COST CONTROL; DONOR; ERYTHROCYTE TRANSFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITAL DEPARTMENT; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PEDIATRICS; PRIORITY JOURNAL; RELATIVE; RETROSPECTIVE STUDY; SCREENING TEST; TREATMENT INDICATION; WORKLOAD;

ADOLESCENT; ADULT; AGED; ANTIBODY FORMATION; BLOOD GROUP ANTIGENS; CHILD; CHILD, PRESCHOOL; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; ISOANTIBODIES; ISOANTIGENS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 10744224304     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704114     Document Type: Article

References (31)

1. Powles R, Mehta J, Kulkarni S et al. Allogeneic blood and bone-marrow stem cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 335: 1231-1237.
2. Gratwohl A, Passweg J, Baldomero H et al. Hematopoietic stem cell transplantation activity in Europe 1999. Bone Marrow Transplant 2001; 27: 899-916.
3. Jantunen E, Myllykangas-Luosujarvi R. Stem cell transplantation for treatment of severe autoimmune diseases: current status and future perspectives. Bone Marrow Transplant 2000; 25: 351 356.
4. Krivit W, Peters C, Shapiro EG. Bone marrow transplantation as effective treatment of CNS disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy and Sly syndromes, and Gaucher disease type III. Neurology 1999; 12: 167-176.
5. Rubinstein P, Carrier C, Scaradavou A et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339: 1565-1577.
6. Haas R, Witt B, Mohle R et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995; 85: 3754-3761.
7. Mohandas K, Aledort L. Transfusion requirements, risks, and costs for patients with malignancy. Transfusion 1995; 35: 427 430.
8. Mehta J, Powles R, Singhal S et al. Transfusion requirements after bone marrow transplantation from HLA-identical siblings: effects of donor-recipient ABO incompatibility. Bone Marrow Transplant 1996; 18: 151-156.
9. Lapierre V, Kuentz M, Tiberghien P et al. Allogeneic peripheral blood hematopoietic stem cell transplantation: guidelines for red blood cell immuno-hematological assessment and transfusion practice. Bone Marrow Transplant 2000; 25: 507-512.
10. de la Rubia J, Arriaga F, Andreu R et al. Development of non-ABO RBC allo-antibodies in patients undergoing allogeneic HPC transplantation. Is ABO incompatibility a predisposing factor? Transfusion 2001; 41: 106-110.
11. Schonewille H, Haak HL, van Zijl AM. Alloimmunization after blood transfusion in patients with hematological and oncologic diseases. Transfusion 1999; 39: 763-771.
12. Przepiorka D, Weisdorf D, Martin P et al. 1994 Consensus conference on acute GvHD grading. Bone Marrow Transplant 1995; 15: 825-828.
13. Dreger P, Viehmann K, von Neuhoff N et al. Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumour eradication, reconstitution of hematopoiesis and immune recovery. Bone Marrow Transplant 1999; 24: 153-161.
14. Rambaldi A, Borleri G, Dotti G et al. Innovative two-step negative selection of granulocyte colony-stimulating factor mobilized circulating progenitor cells: adequacy for autologous and allogeneic transplantation. Blood 1998; 91: 2189-2196.
15. Balduzzi A, Gaipa G, Bonanomi S et al. Purified autologous grafting in childhood acute lymphoblastic leukemia in second remission: evidence for long-term clinical and molecular remission. Leukemia 2001; 15: 50-55.
16. Conover WJ. Practical Nonparametric Statistics. 2nd edn. Wiley: New York, 1980.
17. Ting A, Pun A, Dodds AJ et al. Red cell alloantibodies produced after bone marrow transplantation. Transfusion 1987; 27: 145-147.
18. Dumont-Girad F, Roux E, van Lier RA et al. Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants. Blood 1998; 92: 4464-4471.
19. Nordøy T, Kolstad A, Endresen P et al. Persistent changes in the immune system 4-10 years after ABMT. Bone Marrow Transplant 1999; 24: 873-878.
20. de Vries E, van Tol MJD, van der Bergh RL et al. Reconstitution of lymphocyte subpopulations after pediatric bone marrow transplantation. Bone Marrow Transplant 2000; 25: 267-275.
21. Steingrimsdottir H, Gruber A, Björkholm M et al. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications. Haematologica 2000; 85: 832-838.
22. Uderzo C, Fumagalli M, De Lorenzo P et al. Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation. Bone Marrow Transplant 2000; 26: 1005-1009.
23. Corti P, Uderzo C, Tagliabue A et al. Defibrotide as a promising treatment for thrombotic thrombocytopenic purpura in patients undergoing bone marrow transplantation. Bone Marrow Transplant 2002; 29: 542-543.
24. Balduzzi A, Valsecchi MG, Silvestri D et al. Transplant-related toxicity and mortality: an AIEOP prospective study in 636 pediatric patients transplanted for acute leukemia. Bone Marrow Transplant 2002; 29: 93-100.
25. Gustafsson Å, Remberger M, Winiarski J, Ringdén O. Unrelated bone marrow transplantation in children: outcome and a comparison with sibling donor grafting. Bone Marrow Transplant 2000; 25: 1059-1065.
26. Worel N, Greinix HT, Schneider B et al. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: a major ABO mismatch means problems. Transfusion 2000; 40: 543-550.
27. Rowley SD, Liang PS, Ulz L. Transplantation of ABO-incompatible bone marrow and peripheral blood stem cell components. Bone Marrow Transplant 2000; 26: 749-757.
28. Redman M, Regan F, Contreras M. A prospective study of the incidence of red cell alloimmunisation following transfusion. Vox Sang 1996; 71: 216-220.
29. Garratty G. Evaluating the clinical significance of blood group alloantibodies that are causing problems in pretransfusion testing. Vox Sang 1998; 74(Suppl. 2): 285-290.
30. Godthelp BC, van Tol MJD, Vossen JM, van der Elser PJ. T-cell immune reconstitution in pediatric leukemic patients after allogeneic bone marrow transplantation with T-cell-depleted or unmanipulated grafts: evaluation of overall and antigen-specific T-cell repertoires. Blood 1999; 12: 4358-4369.
31. Abou-Elella AA, Camarillo TA, Allen MB et al. Low incidence of red cell and HLA antibody formation by bone marrow transplant patients. Transfusion 1995; 35: 931-935.